Join to access to all OVN content. Join for Free
How to create HIGH performing MSLs, teams and MSL leaders
field medical development evolving role of MSLs executive coaching soft skills for MSLs high-performing MSL teams

How to create HIGH performing MSLs, teams and MSL leaders


Share This Article


Summary

In this episode, Mike Penkethman delves into field medical development and the evolving role of MSLs. He emphasizes the importance of executive coaching, soft skills, and adapting to pandemic-driven changes. Mike provides insights into the attributes of high-performing MSLs, especially in virtual settings, and discusses the evaluation of MSL teams. He highlights strategies for team development, goal setting, and the significance of networking and centers of influence. The conversation also covers practical advice on verbalizing and documenting goals, honing soft skills, and crafting a compelling CV for aspiring MSLs. The episode concludes with reflective closing remarks and gratitude.

Check out my latest podcast with Mike Penkethman, Career Coach and President of the Pilotage Group. We discuss how to create high-performing MSLs, teams, and MSL leaders.

We discuss:

 What are the key attributes of high performing MSL
 What MSL interactions will look like in the future
 What do MSL Leaders look for in MSLs
 What is the most successful approach to KOL interactions
 What value and resources can (and should) MSLs bring to their KOLs

Click for Source
field medical development, evolving role of MSLs, executive coaching, soft skills for MSLs, high-performing MSL teams

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Explore OVN